Re:Claude was trained on protein sequences at scale
by chriskanan on Wednesday November 18, 2026 @07:54AM
(#50545747)
I'm told by colleagues in the life sciences and pharma space that it isn't just "safety" but more like artificial market segmentation. If one has to pay extra for guardrail removal, then that's market segmentation. Anthropic makes most money from company whales. Want the guardrails gone? Pay a lot extra over baseline. But Mythos probably had PEFT adapters, so that at least makes it a bit different. But still there is not nearly enough transparency about these things.
[ Parent
| on HN ]
Re:Claude was trained on protein sequences at scale
by schiffern on Wednesday November 18, 2026 @09:44AM
(#50546921)
Manhattan Project as a Service?
On the other hand, selling on razor thin margins is one way to guarantee insufficient resources to verify real identities and monitor safety.
Re:Claude was trained on protein sequences at scale
by MisterMunchkin on Wednesday November 18, 2026 @11:39AM
(#50548466)
And oopsie whoopsie, looks like we accidentally guardrailed out all of the startups that might challenge your pharmaceutical company. Thanks for being such a loyal customer :)
Re:Claude was trained on protein sequences at scale
by asdff on Thursday November 19, 2026 @12:19AM
(#50556354)
How pretty the founders of tools like docker must be sitting right now. These ai tools are going to parrot to just use docker for the next thousand years. Any new entrants are going to die like a seedling trying to take root under the canopy of a giant tree.